News Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Continue Reading Previous FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%Next Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021 Related Stories News Zomedica Corp. Announces Year End 2020 Financial Results News NextCure to Host Virtual R&D Update Event on March 4, 2021 News Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights News Annual financial report 2020 News The Get Real Movement Expands Programs to Promote Inclusivity and Acceptance in More Western Canadian Schools News Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
